春节假期刚过，上海嘉定的一个科技园区里一片繁忙。这里是"联影小镇"，由嘉定工业区与联影集团共 建。中午，联影医疗磁共振事业部联合创新部总监袁健闵刚从医院赶回公司，电梯门一开，他拎着电脑 包直奔会议室，外套还没来得及脱，电脑已经接上屏幕，一段磁共振影像开始播放。 "上午医生又提了个细节：肿瘤的边界画面能否再清晰一些？"与其说袁健闵在做研发，不如说他在 做"翻译"：他要把医生在使用中的直觉和经验，拆解成工程上可以执行的修改点，再把调整后的方案带 回医院继续验证。 这样的往返，他几乎每周都会经历两次以上。支撑这一节奏的，是周围逐渐成形的协作网络。园区与医 院、高校、科研院所之间的距离被不断拉近，一个想法从提出到讨论，往往只需要半天时间。 从联影集团出发，车程不到5分钟，就到了上海六晶科技股份有限公司。六晶科技创新中心负责人刘文 迪也在"连轴转"。上午，他在上海的会议室里和同事讨论优化方案；下午，又赶到半小时车程外的江苏 太仓的实验室，看一批新材料的实验结果。 在医疗影像设备领域，钨是绕不开的原材料，密度高、屏蔽性能好，但它的价格高、波动大。实验室 里，不同配比的合金样件轮番上机检测。一次不行，换方案；数据不理想，调 ...

Core Viewpoint - The medical technology industry is navigating through change and uncertainty, with accelerated innovation, improved regulatory frameworks, and evolving global market dynamics [1] Group 1: Industry Progress and Contributions - Every professional in the medical technology field is contributing to change through various roles, from laboratory testing to market engagement [2] - These diverse efforts collectively drive the continuous advancement of the medical technology industry [3] Group 2: Future Outlook and Challenges - The industry is entering a new phase by 2026, where the focus shifts from mere technological innovation to the practical application and market dynamics of these innovations [5] - Key questions for the future include how technology can effectively enter clinical settings, enhance medical efficiency and quality, and create long-term value in real-world scenarios [7] Group 3: Strategic Directions - Innovation is evolving from product competition to a focus on systemic capabilities and comprehensive solutions [6] - The industry faces a new strategic balance between globalization and localization [6] Group 4: Company Initiatives - The company aims to deepen the understanding of medical technology innovations and industry trends, serving as a platform for future industry discussions [8] - Plans include building a systematic knowledge framework for niche markets, creating valuable industry conferences and white papers, and establishing a dialogue platform connecting research, clinical practice, and industry [10]

Core Insights - The development logic of medical technology is shifting due to the upgrade of medical demand, engineering technology iteration, and the evolution of payment systems, with a focus on system-level solutions and industry collaboration [2] - The third Global MedTech Conference will be held on June 12, 2026, at the Zhongguancun Conference Center, aiming to connect engineering, clinical, corporate, capital, and regulatory aspects of medical technology innovation [2] - The conference will feature the release of a white paper, award evaluations, and multi-theme forums to present global medical technology innovation trends [2] Conference Overview - The conference will include a brand exhibition area for showcasing innovative technologies, products, and solutions, with reservations now open [3] - The second Global MedTech Conference highlighted the release of the "2026 Global Medical Technology Innovation White Paper" and awarded 11 innovation awards [4][6][7] - The white paper will provide a comprehensive framework for industry observation, focusing on technological evolution, product changes, corporate development models, and industry patterns [13][14] Key Themes - The white paper will cover high-end medical devices, surgical robots, medical imaging, digital healthcare, and the trends in registration and commercialization [15] - The conference will also feature awards for various categories, emphasizing long-term capabilities and systemic innovation [16][20] - Multi-theme forums will address topics such as medical technology innovation trends, engineering technology changes, and the commercialization path from R&D to market [17] Audience and Participation - The conference targets a diverse audience, including clinical experts, medical technology company leaders, industry observers, and investment representatives [21] - Sponsorship opportunities will provide structured, compliant, and sustainable collaboration paths for companies [22] - The event is positioned as an industry-focused, research-oriented conference rather than a purely academic or promotional meeting [23]

Core Insights - The article highlights the significance of the Boao Lecheng International Medical Tourism Pilot Zone as China's only "medical special zone," serving as a key window for high-level openness and quality development of Hainan Free Trade Port [1] Group 1: Medical Tourism Growth - In the past year, medical tourism in Lecheng surpassed 860,000 visits, marking a year-on-year increase of 109% [1] - Medical revenue exceeded 8.39 billion yuan, reflecting a year-on-year growth of 51.5% [1] - Over 9,300 international patients from 14 countries and regions visited Lecheng, with a sixfold increase in numbers post-border reopening, indicating a trend of seeking medical treatment in China [1] Group 2: Innovation in Medical Technology - Lecheng introduced over 100 types of global innovative drugs, medical devices, special medical foods, and health products last year [1] - Notable advancements include the introduction of China's first boron neutron capture therapy system, which targets tumor cells precisely without harming healthy tissue, offering new hope for cancer patients [1] Group 3: Future Aspirations - By 2025, Lecheng aims to become a world-class medical tourism destination and a platform for medical technology innovation, facilitating domestic patients to receive care without going abroad and attracting international visitors for health services [1]

Core Insights - The Hainan Boao Lecheng International Medical Tourism Pilot Zone is emerging as a new destination for international medical tourism, with over 860,000 medical tourism visits in the past year, representing a 109% year-on-year increase [1] - Medical revenue in the zone exceeded 8.39 billion yuan, marking a 51.5% increase compared to the previous year [1] - The zone has attracted over 9,300 foreign patients from 14 countries and regions, with a sixfold increase in foreign patient visits following the full closure of Hainan's free trade port [1] Group 1 - The zone has introduced over 540 types of urgently needed clinical drugs and medical devices that are not yet listed in China, achieving synchronization with global advanced standards [1] - In the past year, the zone has successfully introduced over 100 types of global innovative drugs and medical devices, including advanced technologies such as the first boron neutron capture therapy system in China and Histotripsy ultrasound tissue fragmentation technology for tumor treatment [1] Group 2 - The service system in the zone is being developed, including the establishment of Hainan's first wholly foreign-owned hospital and the creation of a one-stop cross-border insurance service platform [2] - The "Lecheng Special Drug Insurance" has been upgraded to include Hainan residents, enhancing the accessibility and convenience of cross-border medical services [2] - The zone aims to become a world-class medical tourism destination and a platform for medical technology innovation, marking the beginning of its development under the "14th Five-Year Plan" [2]

Group 1 - The core viewpoint of the news highlights the positive momentum in the medical innovation sector, driven by the National Healthcare Security Administration's initiatives to support pricing for innovative medical technologies [1][2] - The China Securities Index for medical and medical device innovation (931484) shows mixed performance among its constituent stocks, with notable gains from companies like Yingke Medical and New Horizon [1] - The Medical Innovation ETF (516820) has seen significant net inflows, totaling 51.78 million yuan over four days, indicating strong investor interest in the sector [1] Group 2 - CITIC Securities anticipates that the expansion of the National Healthcare Security Administration's pricing directory will facilitate faster national pricing and hospital admission processes for innovative medical devices, addressing previous challenges in the market [2] - The index comprises 30 publicly listed companies with strong profitability and growth potential, reflecting the overall performance of the medical and medical device sector [2] - As of December 31, 2025, the top ten weighted stocks in the index account for 63.75% of its total weight, including major players like WuXi AppTec and Mindray Medical [2]

Investment Rating - The industry investment rating is "Increase Holding" [2][5] Core Insights - The recent release of the "Guidelines for the Pricing of Surgical and Treatment Auxiliary Medical Services" by the National Medical Insurance Administration aims to standardize pricing for innovative medical technologies, including surgical robots, which is expected to accelerate clinical application [4] - The guidelines introduce a tiered pricing model based on the level of participation and clinical value of surgical robots, allowing for higher fees for more advanced functionalities [4] - The establishment of a new pricing project for "Remote Surgical Assistance" facilitates the practical application of remote surgery, enhancing access to quality medical resources across regions [4] - The guidelines clarify the boundaries between consumable costs and technical service fees, promoting transparency and reducing unreasonable price increases in the industry [4] - The inclusion of medical data storage and device operation records in the pricing structure is expected to support future technological iterations and application expansions [4] Summary by Sections Industry Overview - The industry comprises 133 listed companies with a total market value of 14,628.56 billion and a circulating market value of 13,032.75 billion [2] Policy Impact - The new pricing guidelines are anticipated to break the commercialization bottleneck of surgical robots, emphasizing the need for continuous innovation among companies [4] - Companies with technological accumulation and high product maturity, such as Tianzhihang-U, Jingfeng Medical-B, and others, are expected to benefit from the inclusion of robotic-assisted surgery projects in local medical insurance directories [4]

Group 1 - The National Healthcare Security Administration (NHSA) issued the "Guidelines for the Pricing Project of Surgical and Treatment Auxiliary Medical Services (Trial)" to standardize pricing for innovative medical technologies, including 3D printing and robotic surgery, establishing 37 pricing items and additional charges [1][2] - The guidelines aim to create a unified pricing framework for surgical robots and remote surgeries, allowing innovative products to achieve reasonable premiums and promoting the flow of quality medical resources [1][2] - The guidelines introduce a new pricing project for remote surgical assistance, enabling experts in resource-rich areas to provide remote surgeries to patients in other regions, thus reducing the burden of travel for patients [2] Group 2 - The NHSA plans to complete the compilation of the guidelines to achieve a basic unification of medical service pricing projects nationwide, improving the quality and efficiency of the review process for new pricing projects [2] - The pricing framework for surgical robots will be based on their level of participation in surgeries, with higher fees for robots that are more involved and precise, while also considering cost-sharing and patient accessibility [2][3] - The establishment of a national unified pricing for surgical robots is expected to promote the widespread application of robotic surgery technology, enhancing the commercialization process of innovative medical equipment [3][4] Group 3 - The guidelines are anticipated to encourage domestic R&D enterprises, shorten the promotion cycle of new technologies, and drive down costs in the domestic supply chain [4] - The focus on the clinical value of robotic surgery is expected to guide and incentivize companies to develop high-value technologies that can participate more deeply in core surgical procedures [3] - The guidelines will help resolve clinical translation issues for innovative technologies like precision navigation and surgical robots, benefiting patients and promoting high-quality development in the medical equipment industry [3]

Core Insights - The National Healthcare Security Administration (NHSA) released a guideline focusing on pricing for surgical and treatment auxiliary operations, emphasizing advanced medical technologies such as 3D printing and robotic surgery [1][2] Group 1: Pricing Guidelines - The guideline establishes 37 pricing items, 5 additional charges, and 1 expansion item, aiming to standardize pricing for innovative medical technologies [1] - Pricing is categorized based on the level of robotic participation in surgeries, with three tiers: navigation, participation, and precision execution, promoting the use of advanced surgical robots in complex procedures [1][2] Group 2: Impact on Healthcare - The pricing initiative is expected to facilitate the transition of remote surgeries from experimental stages to practical applications, benefiting patients, healthcare institutions, and pharmaceutical companies [2] - The guideline aims to enhance the accessibility of quality medical resources across regions and innovate the hierarchical diagnosis and treatment model [2] Group 3: Cost Considerations - The guideline specifies that auxiliary operation fees should reflect the clinical value and usage costs of consumables, prohibiting simultaneous charges for disposable materials and corresponding auxiliary operation fees [2] - To ensure quality control and traceability in robotic and remote surgeries, the guideline includes requirements for storing and uploading medical data and equipment operation records, with penalties for non-compliance [2]

Core Viewpoint - The release of the National Medical Insurance Administration's guidelines on surgical and treatment auxiliary medical service pricing is expected to drive the clinical adoption of innovative technologies, particularly in the field of surgical robotics, benefiting companies like Precision Medicine-B (02675) [1] Company Summary - Precision Medicine-B (02675) has seen its stock price increase by over 9%, reaching 64.8 HKD with a trading volume of 23.0585 million HKD [1] - The company is recognized as a leading surgical robotics firm in China's medical device industry, focusing on the design, development, and manufacturing of surgical robots [1] - According to Frost & Sullivan, Precision Medicine is the first company in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] Industry Summary - The National Medical Insurance Administration has issued a guideline that includes 37 pricing projects, 5 additional charge items, and 1 expansion item, focusing on advanced medical technologies such as 3D printing and robotic surgery [1] - The implementation of these guidelines is expected to standardize the pricing and project establishment for surgical robots across provinces, promoting the clinical use of innovative technologies and driving demand for terminal equipment and surgical assistance [1]